AsianScientist (Nov. 26, 2013) – Mallinckrodt Pharmaceuticals has entered into a partnership with China Resources Pharmaceutical Co., Ltd. for the promotion of Optiray™ (ioversol injection) x-ray contrast media in China.
Optiray (ioversol injection) x-ray contrast media is a non-ionic, low viscosity iodine based contrast medium that is administered through intravascular routes to enhance diagnostic imaging procedures.
“Through this collaboration with China Resources Pharmaceutical, Mallinckrodt looks forward to increasing our ongoing commitment to grow sales of imaging products in the PRC,” said Stephen Merrick, President, International Commercial Operations at Mallinckrodt.
“Contrast media products to be covered under this agreement will be used for X-ray, computed tomography or cardiovascular procedures.”
——
Source: Mallinckrodt Pharmaceuticals.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.